Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Revenio Interim Report Q3/2024

By Inderes10/31/2024, 1:00 PM
Revenio Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jouni Toijala
00:00 - 11:28

Good afternoon, and welcome to the Revenio Group Q3 earnings call. My name is Jouni Toijala, and I'm the group CEO. And we have here as well. Uh, Robin Pulkkinen, our CFO. Today, I'm going to start by going through the highlights for Q3. So, a bit of numbers then, highlights from the business and products. Then Robin is going to go through the financials in more detail and then finish up with the shareholders and reiterate the financial guidance. So, let's jump to Q3. So, it was a good quarter in terms of organic sales growth for us. Net sales reached 23.9 million, an increase of 8.9% from last year, which was at 22 million. And it should be noted that we experienced significant currency headwinds from the US dollar to euro exchange rate. So, if you look at the growth from the currency-adjusted point of view, Q3 growth for July to September was actually 15.1% in operating profit, accounting for 23% of the net sales. So, $5.5 million, down from $6 million last year. And here, perhaps a couple of comments related to profitability. So we got the headwind effects, roughly 10. €9 million. So, roughly a bit more than 50% actually goes through the EBITDA line as well. And then this was a really good quarter for us. What comes to launching the new product. So we have a new tonometer, the iCare ST500, now out. Then we have the TONOVET Pro, also a new tonometer. We have been spending quite a lot of additional marketing money for the global launches of these products. But Robin is going to cover in more detail the cost side in his presentation and net cash flow from operations was 2.9 million, down from 5.6 million. But if we then look at the whole January to September highlights from the numbers perspective, we see extremely strong cash flow: 14.1 million, up from 5.6 million. And if we look at the sales growth for the first nine months. So, we are currently at 5%. And if looking at it from the guidance perspective. So, currency-adjusted growth on the sales side is 8.99%. But, if we jump next to the business highlights for Q3 2024. It was an extremely good quarter for us from the product perspective and from the regulatory approval perspective. A couple of comments related to that one. So, if we look at the sales in general, the sales of fundus imaging devices saw double-digit growth year on year. And again, the main growth products were the iCare EIDON family, and also the iCare DRSplus from the tonometry side had a good quarter as well. iCare HOME2 was actually one of the highest growing devices from the tonometer perspective, and from the imaging product portfolio. The iCare IC200 is growing well, and the newly launched iCare TONOVET Pro is getting extremely good traction. And of course, probes have been showing particularly strong performance in terms of growth as well. Then, positive news from China. So, we got the approval for iCare EIDON in China. Also the iCare IC200 Quick Measure. The tonometry feature, of course, along with the hardware, was then approved and received marketing authorization in China. So, this is actually really good news. These projects tend to take time. So as an example in the iCare case, we started the project already almost three years ago. And these projects are really, really time-consuming. So now we have a really good product portfolio available in China. So that's a plus. That's a plus. Then the Tonometers as well. So that's extremely good news for the future. And then there was also news during Q3 from the AI perspective. So we acquired a Dutch company called Thirona Retina. And the logic there was to get the assets on the AI platform. So we have been working with Thirona for a long time in the context of retina screening. So meaning together with the Iluma and iCare DRSplus. Plus, this enables us to now own the assets. We have the freedom to decide the business model, have a better margin, and in this context, nothing is going to change. So we are going to work with other AI players. Plus, we are going to guarantee that the support from Thirona Retina is going to continue. Also for other players like Topcon, like Canon, etc. , with whom they are working. So. So there is no plan to change this one at all. Then, in addition to having and using a Thirona Retina B.V. From a clinical decision support perspective, another rationale for the acquisition was that AI is increasingly gaining importance within the device and across its various functions. So now we have skills and capabilities also in-house for that one and for future development of the devices, and then not so good news from the CMS perspective, i.e. The reimbursement code for the hardware for the iCare HOME2. So the decision was not to grant the durable medical equipment reimbursement code for iCare HOME2. And the reason was that you already have a good set of codes which you and your doctors are able to use. So the codes currently are codes for training, renting the device out, telehealth and remote monitoring, and data analysis. So that was the logic. So what does that mean for us. So we are going to continue the work around those codes and still want to remind everybody that if we look to Q3. So iCare HOME2 was the highest growing product segment for us. Then, we also launched the iCare ST500 slit lamp-mounted tonometer during Q3. And this is actually the continuation of the things that we said on April 1st, 2020, in our CMD. And I'm sure somebody remembers from the call audience that we said the long-term goal for us in tonometry is to make rebound technology the gold standard, replacing the Goldmann tonometer, which is more than 70 years old. So, this also partly answers that question. So what we are going to gain from the slit lamp mounted tonometer is that we haven't had a fully blown product portfolio for all patient workflows. So the patients who are going to undergo slit lamp examination. Mainly, Goldmann tonometers have been used to measure the IOP. So now we have a product for that one, and it fully complements our other rebound tonometers, iCare IC100, iCare IC200, and HOME. Then another important part is that if we think about the Goldmann assay, a method of measuring the IOP, it's not fully reliable. So, if you measure the patient at the clinic with the Goldmann tonometer and then, as an example, with iCare HOME2 at home, you get unreliable measurements in most cases, or at least not repeatable if you use the Goldmann. So now we have clinical proof that the entire platform, whether you measure the IOP with iCare IC100, iCare IC200, iCare HOME2, or test the ST500, is fully repeatable and completely comparable. So it's going to improve. Then, the patient care improves from that perspective. So, so, really good. And then perhaps thirdly I have to mention that this is not only the ST500. So, what is inside the device. It's totally new. So we have a totally new hardware platform inside the device, which we are going to use in the forthcoming new tonometers in years to come. A very significant product for us if we think of it from the long-term perspective. Then we also got the timing right. Product is good to go. We already have orders in. We are able to produce it. We are able to ship. At the same time, we have FDA clearance. Plus, we have the CE mark for the device. So from that perspective, it's really good news and we're good to go. So let's switch gears and move to the financial side. So, over to you, Robin. Thanks, Jouni.

Robin Pulkkinen
11:29 - 17:51

So, going through it a bit more in detail. Like you mentioned, the sales were growing organically quite well. We are quite satisfied with the top line. Unfortunately, things that we couldn't control were on the FX side, which did hit us quite hard during the quarter, and um, it kind of shows on the top line. So the pH-adjusted growth was more than 6% greater than the reported growth. Um, and due to our cost structure, a lot of that effect hits the gross margin line, which is the main driver for the gross margin to drop below 70 in the quarter. Additionally, on the EBITDA and EBIT line, we incurred some one-off costs during the quarter similar to the comparable quarter, but they were quite minor. So, you do have the operating profit here and the adjusted operating profit. But there's not a huge difference between those lines. But it's shown separately here as there were certain one-off costs. Um, which are adjusted. Um, so year to date 73 million in sales and that growth is 8.2%, pH adjusted 8.9%. Showing a bit more history. So on the top line, the quarterly fluctuations, looking at the last quarter, we would have been probably pretty close to the trend line without the FX impact, but it seems like the FX has come down a lot since the end of the quarter. So end of September peaked pretty high, and now it’s down multiple percentages again. So, it's interesting to see how it plays out now during Q4 and what the impact will be. But if it decreases, it should have a positive impact on the Q4 numbers. So, profitability is slightly down. Um, so the one big driver is the FX impact, which we've been discussing here, but we also had direct costs that increased. Uh, you only mentioned the marketing costs. So, those elements together with the personnel costs accounted for roughly 85% of the cost increase year over year. And on the personnel side, you might remember from last year, we had very minimal bonus payouts. So the accrual levels are higher now for this year as we are within the guidance and holding to the guidance for the whole year. So that's one of the major parts of the cost increase, together with the marketing, which was actually quite significant. The clinical trials didn't have a notable impact during the third quarter. We're still looking and working with the FDA to understand the scope of the trials, and hopefully, those will start to run again this quarter. So Q4 um, but they haven't yet started. So, I guess that still needs to be worked out as to how that's going to unfold. Year to date, net cash flow is at an impressive level. It's actually on a record level. So, looking at it, it's actually quite interesting when you consider the net profit for the first nine months. We're at the exact same net profit as last year during the first nine months. Our cash flow from operations is up 150%. Um, that improvement is mostly coming from working capital. So, a more effective management of the working capital and also slightly lower paid taxes. But the working capital, our accounts payable (AP) inventory, is the major player there. And then, of course, the beginning of the year bonus payments were pretty low, which is one reason for the first quarter to be quite good. The balance sheet continues to be strong and get stronger. So the total balance sheet value increased slightly from 128 to 132 year over year. On the asset side, the acquisition shows that, on the flip side of the coin, the cash is down slightly. Equity is up, and both short-term and long-term liabilities are slightly down. So typically, looking at the net gearing for our company, the dividend payouts bring up the number. So during the second quarter and then the third, fourth, and first quarter, we build up the cash reserves. Now in Q3, we did pay out for the coronavirus. But basically looking into Q4, we would be pretty fair to expect that line to turn down again for the next report. On the shareholder side, there have not been many changes. We have 23,324 shareholders at the end of the quarter. Uh, the Finnish ownership actually went down roughly from 20.49% to 47.7%. And on the top owner list, there are not really any changes. So the number eight has dropped to number 11. But that’s the only change in the top ten list. And then the countries split here. So, Denmark almost fully meets demand. And then we have Sweden over 10%, US 8.3% and France 4.3%. Ownership and guidance regarding the Revenio Group exchange rate. Adjusted net sales are estimated to grow 5 to 10% from the previous year, and profitability, excluding non-recurring items, is estimated to remain at a good level. So basically, when you do the math, we expect to celebrate our first 100 million year sometime during this quarter, hopefully sooner rather than later. But to keep the guidance means that we have to exceed 100 million in sales this Q4.

Jouni Toijala
17:53 - 17:58

Excellent. Thank you. Robin. It's time for the questions, please.

Operator
18:04 - 18:27

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Nico Ruokangas from SEB. Please go ahead.

Nico Ruokangas
18:31 - 19:08

Hello. This is Nico from SEB. Thank you for the presentation. I have a couple of questions. And starting with that, you said that the investments by PR-driven opticians continue to move slowly, and the slight positive momentum seen during H1 has not yet materialized in large orders. So, have you still seen the positive momentum despite not having larger orders yet? And then on the other hand, when do you expect the orders to start materializing?

Jouni Toijala
19:09 - 19:54

So the status quo remains unchanged. So, the status remains pretty much the same as before. So we are getting orders, but not the big, large orders. So not on the big chunks, but I mean here and there. And so, in that sense, it remains the same. And then, of course, the question remains as to when it's going to turn. So I don't have a full question. Sorry, I don't have a full answer to that one yet. So. But I mean the sentiment has been the same, with orders popping in, but not in huge chunks. And it used to be earlier. So, in that sense, the status is the same.

Nico Ruokangas
19:55 - 20:06

All right. Understand any other changes to your outlook compared to the Q2 report?

Jouni Toijala
20:07 - 20:46

I mean, no, no. So, precisely the same logic. So, if we look at what we have been communicating. So, Q1 was more or less on par with the previous year, Q2 and Q3 showed good growth. And then again, when we go to watch Q4. So, as we have said earlier, most of the growth for the full year. If you look, the whole full year's growth is coming from Q2 and Q3 predominantly. Robin, would you like to add anything to that?

Robin Pulkkinen
20:46 - 21:10

Yeah, I think the Q4 comparables were challenging, similar to Q1, and I believe the year has played out very much as we've been discussing all year. In Q1, we assumed that Q2 and Q3 would bring the biggest growth. And then Q4 is a more challenging quarter for us. And I think the situation has played out pretty much as we expected it to.

Nico Ruokangas
21:13 - 21:36

Yeah. Understood. Then I would like to again ask a question regarding competition, which has been discussed quite many times, but has become a more visible competitor to you in either Europe or the US. And has the competitive situation affected your pricing?

Jouni Toijala
21:37 - 22:19

We have been very active at a couple of trade shows where the activity has been significant. So, Esther was at AAU about two weeks ago. So, I mean, there has been no impact on the sales, no impact on our pricing. So they have been surprisingly quiet still. And if you look at our meter growth and the probe growth, so far so good. But as before. So remaining humble and vigilant from that perspective. But the status is exactly the same as it was during Q2.

Nico Ruokangas
22:21 - 22:46

I understand, then, the FDA costs. So, you say that there were not much in Q3, so how much is still left? And then, does it mean a delay, or does it indicate a delay in the process such that the trials are not currently ongoing?

Jouni Toijala
22:47 - 24:30

I could answer that one. So we have done two press-ups for the FDA. FDA. So, let's perhaps discuss that before I go there. Let’s understand what has been going on with the FDA costs in general. So, we have had products in the pipeline. So the $500,000 is generating the FDA cost. Of course, those are essentially gone. The clinical studies are concluded. We have clearance from the FDA. And then we have been working on the clinical studies related to the next-generation Mya Mya. So those costs have been coming in. And then what comes to the Illume Thirona Retina B.V. Icare DRSplus. So there, we have been conducting the precepts in order to define the scope of the clinical studies. Right. And we have conducted two precepts now. And now we have the FDA approval, and we are still going through the feedback. And really, the logic is that we don't want to rush and we want to get it right. So it would be a shame to conduct a long clinical study and pay 1 to 1.5 million. And then the FDA comes and says, 'Hey, you didn't take this small part into account', and then we should run the clinical studies again. So this is where we stand now. So we haven't yet started the clinical studies and we haven't begun enrolling patients, because we want to ensure that everything proceeds correctly with respect to FDA requirements. So that's the current status, okay.

Nico Ruokangas
24:30 - 24:40

So that will still bring another 1 to 1.5 million euros of costs during Q4 and H1.

Robin Pulkkinen
24:40 - 25:12

We did have some in Q1, but yes, the scope and the number of patients needed. I don't think any of that is yet locked. And if you still need to adjust or do a new pre-submission, that would mean that probably there won't be any cost in Q4 either. Um, but we don't know yet for sure. So, we're talking with the FDA and trying to understand and ensure that whatever studies we start, they meet all the requirements needed to obtain approval.

Nico Ruokangas
25:14 - 25:18

Okay, I understand. That's all from me at this point.

Jouni Toijala
25:18 - 25:20

Thank you. Nico. Thanks.

Operator
25:25 - 25:31

The next question comes from Daniel Lepistö from Danske Bank. Please go ahead.

Daniel Lepistö
25:34 - 26:08

Hi, it's Daniel from Danske Bank. I hope you can hear me well. Apologies. My line has been quite poor during the call, but I have a couple of questions, maybe continuing on that funded opticians topic and your note of there being no larger orders yet? But I guess, looking at the organic growth on an FX-adjusted basis, accelerating quarter on quarter, it seems that you are still doing quite good business. So who are these customer segments now that are driving this growth? At the moment.

Jouni Toijala
26:08 - 27:09

It's the standard segments of optometry and ophthalmology. And then, we have been able to consistently secure new deals every quarter for the Illum package, and by the Illum package, I mean the iris, plus the eye. And the tendency is that we tend to sell those packages outside of our traditional customer segments, i.e. optometry and ophthalmology. optometry, ophthalmology, and Molokai. Of course, it partly relates to optometry. But, that has also been a new segment for us this year where we have been able to sell. But as I mentioned earlier, We have found new clients and growth in the optometry and ophthalmology sectors. And then, as an example, from the diabetic clinics in Europe.

Daniel Lepistö
27:13 - 27:29

Okay. I mean, can you give us any sort of contribution from the Illume? It certainly sounds like it has started to become a bigger contribution to your growth compared to some time ago.

Robin Pulkkinen
27:29 - 28:02

No, I think the traction is good. We have a lot of users coming onto the platform and a lot of reports being run, but revenue-wise, it doesn't yet impact the Illume part. However, the hardware sales are indeed recognized. And as they are being delivered. So those are essentially hardware sales, but they are also directly linked to the software component. But the Illume revenue, of course, is a recurring revenue stream that will begin to play a much larger role in the coming years.

Daniel Lepistö
28:05 - 28:43

All right. Yes, I understand. Good clarification. I guess the second topic is on the SD 500 and its launch. I recall that Goldman technology used to account for about 20% of the total market. And I guess this is now a sort of portion that you can target quite well with this new solution. So is this market share estimate still valid? And are you more confident about capturing a larger portion of the global market share? Looking at the following year and coming years.

Robin Pulkkinen
28:43 - 29:35

I think Goldman is actually more on the lines of if we're at 35%, then Goldman and Air are probably both in the 30s range as well. So, basically, it's a pretty big market, and previously we didn't really have anything to offer to replace the slit lamp-mounted Goldman. So now it's the first time we're able to sell to that segment. So definitely there's good potential. And actually, the product has been very well received in the US and Europe at the trade shows; we attended the AAO and SARS in Barcelona. I think the product drew a lot of attention also within the slit lamp manufacturer. So it's interesting to see how all that's going to play out.

Daniel Lepistö
29:39 - 30:09

All right. That's good. I guess the final question may still be about the new products or product refreshments on the micro perimeter. I assume you've noticed that the first commercial deliveries are expected in early '25. So can you clarify here? You already have a functioning product that is approved. Or do you have an established pipeline for this product, or are these just your expectations that there will be deliveries?

Jouni Toijala
30:09 - 31:54

So, a couple of things there. So, we have ensured that one of the most important things, which we accomplished many months ago, is to guarantee that if we measure a patient with the next-generation measures or the new measure, we get exactly the same results as with the old Maya. So that's done. And we have conducted the clinical studies to prove that. So that's the first hurdle which we have already passed. Then we already have a working device, which indicates that the software is pretty mature. So we have a working device here at our office. So from that perspective, we are in good shape. And of course, the third thing is that we have to get the regulatory approvals. Our current goal is that we would be able to start taking orders and move the business forward towards the first half of next year, and hopefully by Q1. So that's where we currently stand. So nothing has changed from that perspective. And it looks good that we are able to keep the Q1 timeline from that perspective, meaning we are able to start commercial deliveries. Regarding the pipeline, sorry, the details are pertinent to the pipeline. So that has been the unfortunate case; I mean, we would have been able to sell devices if we had them. We have the demand for the device as soon as we can get it out. So that's a good thing.

Unknown 1
31:56 - 31:57

Yeah.

Daniel Lepistö
31:57 - 32:02

All right. That's great to hear. I guess that's all from my side. Thank you for the answers.

Operator
32:07 - 32:37

The next question comes from Jack Reynolds Clark from RBC Capital Markets. Please go ahead. Jack Reynolds. Clark. RBC Capital Markets, your line is now unmuted. Please go ahead.

Jack Reynolds Clark
32:39 - 33:17

Hi, guys. Sorry, I've had a bit of technical issues so far on the call, so apologies if there have been issues hearing me until now. And apologies if the question I'm going to ask has already been answered. But I had a question on the iCare HOME2 device. So, what was the reasoning that CMS gave behind the decision not to reimburse iCare HOME2 separately? And then, on the existing codes, how generous are they? How accessible are these, and how much incremental sales investment do you think is required to grow iCare HOME2 in the US now that these codes aren't going to be available for use separately? Thank you.

Jouni Toijala
33:17 - 35:06

So, to start with the reasons. So they said that you already have codes in use. And I'm answering the second question as well. So they said that you already have training codes in use. So according to my recollection, it's roughly 20 USD or 19 USD. Then, if renting the device. So that's roughly 50 USD and then analysis and monitoring, that's 130 USD. Then. And then you have to analyze the data, follow up, and have a verbal conversation, and so forth. So, there's a pretty good set of codes which doctors are already able to bill. So that was the logic from CMS. Why not give the DME, durable medical equipment code. And then in terms of the sales effort and increasing sales effort. So we go and continue the work as we have been before. So, if we think back to last month or two weeks ago, we had the AAU Oscars. We have had key opinion leaders speaking at the stand. Ike Ahmed, who is considered one of the gurus on glaucoma management in the USA. So? So he was talking to other doctors during the AAU. Then, Barbara Wyczenski spoke during the Oscars. So, we continue according to the same spend as before to sell and to promote the iCare HOME2. And as said, it was the highest growth device for us in terms of the percentages during Q3.

Jack Reynolds Clark
35:09 - 35:10

Great. That's it. Okay. Thanks so much.

Jouni Toijala
35:12 - 35:13

Hey. Thanks, Chuck.

Operator
35:20 - 35:28

The next question comes from Pia Rosqvist Hazami from Carnegie Investment Bank. Please go ahead.

Pia Rosqvist Hazami
35:31 - 36:06

Yeah. Hi. It's Pia here. Hi. And. Hi, Robin. Um, I have a few questions. I still come back to the explanation on the burden from the ethics change. So when I look at the rates, the euro USD rate appears broadly flat in the third quarter. So, can you please again explain what happened in your PNL and in your balance sheet that affected your sales growth rate negatively?

Robin Pulkkinen
36:07 - 37:06

So basically, it's a complicated package, but the US dollar revenue is revalued for the whole year. So it's year to date, revalued every quarter when we do it. And that's based on the weighted or the average exchange rates, but then the balance sheet is revalued at the end of the closing date exchange rate. And they essentially pertain to the balance sheet. Certain values in the balance sheet also get revalued on the top line. So it's an adjustment line, effects adjustment line, on the revenue. And that's also a significant factor there. So it's kind of a combination of those. And it's difficult for an outsider to understand the impacts because there are items that get revalued, which are not visible to you. So, it's a challenging task to try and analyze or predict the outcomes.

Pia Rosqvist Hazami
37:09 - 37:20

Okay. Thank you. Still. So is it the fact that the balance sheet revaluation is the larger explanation now in the third quarter?

Robin Pulkkinen
37:20 - 37:27

It was a big part. Also, I don't have the full split in front of me right now, but there are different items.

Pia Rosqvist Hazami
37:29 - 37:52

All right. Okay. Then, to the business. You say that the sales development of the probes was really strong. So, what do you attribute that growth to? Is it due to higher prices? Is it higher volumes? Is it higher usage? How would you describe the demand for probes?

Jouni Toijala
37:52 - 38:33

We haven't indulged in hype here. So, I only hear. So we haven’t touched the pricing. So, if we look at Q3 one way, it is to consider it through the top line, but then also through the perspective of unit sales growth. We had a really good growth during Q3, also from the unit perspective. We have simply been selling more probes. And the devices, I mean, they have been used more than last year. Q3 was clearly a success, and we have shipped more probes.

Pia Rosqvist Hazami
38:38 - 38:56

Right. Thank you. Regarding the stronger sales to Asia Pacific, can you provide more details at the country level? Is it Japan? Is it China or is it a broader picture?

Jouni Toijala
38:57 - 39:46

So, it depends a bit country by country. Australia has shown strong growth in Q3, picking up well. There are a couple of countries I don't want to go into in detail because of the competitive region. Then I think what is clear from a highlight epoch perspective is actually China because we now have iCare DRSplus in China as an add-on. In China, we have the iCare IC200 available for quick measurements. So, if we review the Q3 APAC numbers. Now, China has also moved the needle during Q3 in terms of APAC numbers. But do you have any insights on this.

Robin Pulkkinen
39:46 - 40:03

I think Australia was the country that performed really well. Yes, and the imaging sales there are significant. However, we do sell to many countries, and they are all a bit different. Some are up, some are down. But those are kind of the two major factors.

Unknown 2
40:06 - 40:06

Okay.

Pia Rosqvist Hazami
40:07 - 40:46

Okay. Then regarding the decision not to grant a reimbursement code for iCare HOME2. So how do you view this, do you think this is a setback? I mean, you still reported very solid or strong growth for Home2. But compared to your expectations, where was the plan to get a single reimbursement code, kind of the key to unlocking faster sales? And how do you view the potential now with doctors having to use multiple codes?

Jouni Toijala
40:46 - 41:45

Of course, we were hoping and of course, we are disappointed that we didn't get the code. But I mean, we continue the work. So again, if we think about this quarter and the status and the feedback we received from investors, notably from AAO, we are increasingly confident that in order to serve the patients with glaucoma effectively, they should be able to measure their pressures at home and follow up on the fluctuations to properly manage their medication. Right. So, we continue the work on that premises. And in order to ensure that patients are receiving the correct medication and so forth. So, the work continues. Of course, it would have been nice to get the code, but the traction is good. There is a clinical benefit. So, we continue to work hard from the home perspective.

Pia Rosqvist Hazami
41:48 - 42:16

Okay. Okay. Thank you. Then. Still, my final question regards your comments on the outlook. I think you mentioned that you feel you have very limited visibility into the future. Are there any new concerns on the horizon that you follow extra carefully, or is this just a general reflection on the current economic environment?

Robin Pulkkinen
42:16 - 42:34

Yeah. Nothing new has really come up. Um, everything seems the same as before. Of course, we can see from many other company reports that the economy hasn't experienced significant growth in the last months, but we keep a close eye on that, of course.

Pia Rosqvist Hazami
42:36 - 42:39

Yeah. All right. Thank you so much. That's all for me.

Operator
42:46 - 42:51

The next question comes from Johnny Sandoval from Nadia. Please go ahead.

Johnny Sandoval
42:54 - 43:26

Yes. Hi. Thanks for the presentation. I have a couple of questions. Maybe getting back to the margins. Gross margins were clearly down year over year and also quarter over quarter. So, I understand that there is the effects impact. But you also mentioned very strong growth in tonometers, which, to my understanding, have higher margins. So, what has actually changed? Is there any cost pressure, price pressure, or is this driven by geographical differences in sales split?

Robin Pulkkinen
43:26 - 44:29

Yes, the effect is, of course, a significant part. A significant portion of the top-line effects directly impacts the gross margin as well. Because of our variable costs, we have the commissions for the US sales representatives as a dollar-based expense. But other than that, there are some components in the devices that are dollar-based. But it really does flow down to the gross margin. That's the biggest single reason. Then, of course, it depends on how much the sales grew for tonometers. For example, if you use that as an example in the US versus the rest of the world where we have our direct sales channel. So, the margins in the US sales are of course a lot higher because we sell direct to the end user, while we leave about 40-45% of the money on the table in every other country in the world where we sell. And then, of course, the product mix we have. The gross margins vary quite significantly between the products. So, a combination of those factors.

Johnny Sandoval
44:31 - 44:45

Okay. Okay. That's clear. Maybe, maybe a broader question as the US elections are closing. Do you actually see any risks from possible tariffs following the elections on your behalf?

Jouni Toijala
44:47 - 45:14

We have actually been thinking about it. And according to my understanding, I think there might be brighter brains on this topic on this call. So if somebody else would like to comment, but as far as I know, I haven't seen too much discussion related to the medical equipment. But if there are insights on this one. So, other shareholders and analysts. So please, please feel free to jump in.

Johnny Sandoval
45:17 - 45:39

Okay, okay. That's clear. Hey, then maybe follow up on this slit lamp. It seems like an interesting addition, but could you give us any indication of your expectations? What are your expectations for sales? Sales in 2025 for this product will just give us some grasp of the potential of the new tonometer.

Jouni Toijala
45:39 - 46:01

Yes. Sorry. Sorry, Jouni. Unfortunately, we don’t disclose those details, but we are currently building the budget for next year. So there's a healthy number on that also for the ST500 like IC 100, IC 200 and for the home and for the probe. I'm sorry, I can't comment on that.

Robin Pulkkinen
46:02 - 46:08

The fastest growing product next year because we don't have many sales this year yet. So yeah, a couple of months of sales.

Jouni Toijala
46:09 - 46:12

So, for sure, the percentage is going to look really good.

Unknown 3
46:13 - 46:14

So, but also.

Jouni Toijala
46:14 - 46:15

Hopefully, the.

Johnny Sandoval
46:15 - 46:16

Starting point.

Jouni Toijala
46:16 - 46:23

Yeah, also hopefully the dollars. But we have a good order backlog for that product already. So that's a good thing.

Johnny Sandoval
46:24 - 46:38

Okay. Good to hear. And then the last one, this maybe goes to Robin. So, can you give any indication of this marketing spend? How much was this, you know, delta to normalize, or so we could take this into account.

Robin Pulkkinen
46:38 - 46:57

It's in the hundreds of thousands. So after the cost increase, marketing spend and personnel expenses are approximately 85%, and it's not an even split of 50 over 50. But maybe the personnel expenses are a bit more than the marketing, but it's a big chunk.

Johnny Sandoval
46:59 - 47:01

Okay. Okay, thanks. That's all for me.

Unknown 3
47:01 - 47:02

Thank you, Ernie.

Operator
47:09 - 47:30

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Unknown 3
47:32 - 47:33

Great. Hey.

Jouni Toijala
47:33 - 48:11

Thank you. I think it's time to conclude the Q3 call, and next time we are going to meet in February. So we have a bit of a change in plans. So we are going to run a webcast because it's a full year and perhaps a slightly more extended earnings call in February. So, really looking forward to seeing you and having the participation in February. And thank you for your participation and have an extremely good end of the year; let's meet again early February. Thank you. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…